Recombinant Human Sclerostin (SOST), Biotinylated

Uniprot Id

Q9BQB4

Target Species

Human

Target Name

SOST

Target Full Name

Sclerostin

Target Function

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.

Target Involvement

Sclerosteosis 1 (SOST1); Van Buchem disease (VBCH); Craniodiaphyseal dysplasia autosomal dominant (CDD)

Target Subcellular Location

Secreted, extracellular space, extracellular matrix.

Target Protein Families

Sclerostin family

Target Tissue Specificity

Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level).

Target Research Area

Signal Transduction

Target Synonyms

BEER; CDD; Cortical hyperostosis with syndactyly; Sclerosteosis; Sclerostin; Sost; SOST_HUMAN; SOST1; UNQ2976/PRO7455/PRO7476; VBCH

Target Background

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.